Murray Ciaran sold $2.0M of ICLR
Murray Ciaran sold 10,000 shares of ICON PLC (ICLR) at $200.18 ($2.00M total) on 2026-11-12.
ICON PLC
ICON is a contract research organization based in Dublin, Ireland, that provides outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, government and public health organizations. Its services cover clinical development from strategy, planning and trial design through study execution and post-market work, as well as consulting, functional outsourcing and laboratory services. Clinical development offerings include Phases I-IV, peri- and post-approval services, data solutions, and site and patient access. Laboratory testing includes bio-analytical, biomarker, vaccine, GMP and central laboratory services. ICON earns revenue by providing services that support clinical development, including clinical trial management, consulting, contract staffing, data solutions and laboratory services. It works through strategic partnerships, preferred-provider arrangements, full-service delivery, functional service provision and standalone services. Its brands and offerings include the Accellacare clinical research network and Accellacare In-Home Services. At December 31, 2025, ICON employs approximately 40,100 people in 97 locations in 55 countries.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ICLR in the last 7 days.
Murray Ciaran sold 10,000 shares of ICON PLC (ICLR) at $200.18 ($2.00M total) on 2026-11-12.
Murray Ciaran sold 3,452 shares of ICON PLC (ICLR) at $205.66 ($0.71M total) on 2026-11-02.
Balfe Barry Edward (Chief Executive Officer) sold 5,175 shares of ICON PLC (ICLR) at an average of $206.66 ($204.91–$209.53, $1.07M total) across 5 trades on 2026-11-02.
Recent ICLR coverage spans insider activity, earnings and market movers.
In the last 30 days, ICLR insiders filed 22 SEC Form 4 transactions — no purchases and 22 sales ($4.2M). The most active reporter was Lyons Emer, Chief Accounting Officer, with 10 filings.
Insider selling can add modest near-term overhang, but this is a routine Form 4 with no stated reason and no 10b5-1 plan.
The insider sale may signal reduced confidence and could pressure the stock price.
Balfe Barry Edward (Chief Executive Officer) sold 5,175 shares of ICON PLC (ICLR) at an average of $206.66 ($204.91–$209.53, $1.07M total) across 5 trades on 2026-11-02.
The insider sale may create modest selling pressure on ICLR.
Earnings beat and raised guidance suggest near‑term upside.
AlphAI scores every news story that mentions ICLR with an AI model for sentiment and relevance, and aggregates insider trades from ICON PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Murray Ciaran sold 10,000 shares of ICON PLC (ICLR) at $200.18 ($2.00M total) on 2026-11-12.
Murray Ciaran sold 3,452 shares of ICON PLC (ICLR) at $205.66 ($0.71M total) on 2026-11-02.
Balfe Barry Edward (Chief Executive Officer) sold 5,175 shares of ICON PLC (ICLR) at an average of $206.66 ($204.91–$209.53, $1.07M total) across 5 trades on 2026-11-02.
Clerkin Nigel Bernard John (Chief Financial Officer) sold 1,488 shares of ICON PLC (ICLR) at an average of $206.66 ($204.91–$209.53, $0.31M total) across 5 trades on 2026-11-02.
Mizuho raised its price target for ICON (ICLR) to $228 from $190, citing recovery momentum. The stock is near its 52-week high after an 82% surge. ICON reported Q3 2026 earnings beating expectations, with revenue of $2.02B and adjusted EPS of $2.66. Several analysts raised their price targets, highlighting strong bookings and margin expansion.
Truist Securities raised its price target for ICON plc (ICLR) to $268 from $209, citing strong bookings and revenue growth. The stock trades near its 52-week high at $214.16. ICON reported Q3 2026 earnings of $2.66 per share on revenue of $2.02 billion, beating estimates. Truist expects mid-single-digit revenue growth and high-single-digit earnings growth by 2027.
US futures rise, led by Nasdaq, as SK Hynix's strong results boost memory-chip stocks and revive AI trade. Alphabet leads gains among Mag 7 stocks. Several companies report earnings, with mixed reactions. Fed decision and earnings from Alphabet and Microsoft are key events today. Oil prices jump on geopolitical tensions.
ICON Public Limited Company reported Q3 Non-GAAP EPS of $2.66, beating estimates by $0.03, and revenue of $2.02B, up $10M from expectations. Revenue declined 0.5% year-over-year.
ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. 1 ICON Reports Third Quarter 2026 Results Third Quarter 2026 Key Highlights ▪ Strong commercial performance with net business wins in the quarter of $3,150 million; a net book- to-bill of 1.56 x and closing backlog of $24.5 billion, up 4.8% sequentially. ▪ Revenue of $2,024.8 mil
BofA Securities upgraded ICON Public Limited Co. (ICLR) to neutral from underweight, citing improved demand for contract research organization services. The bank expects R&D spending growth of ~4% for top 50 biopharma companies by 2027, enhancing visibility. ICLR shares may benefit from this trend, according to the report.